Global AI-based Antibody Development Platform 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI08244205

Publication Date:

August 7, 2024

Pages:

100

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Software [3]

Computing & Electronics [4]

Description:

A critical aspect of a successful pandemic response is expedient antibody discovery, manufacturing and deployment of effective lifesaving treatments to patients around the world. However, typical drug discovery and development is a lengthy multi-step process that must align drug efficacy with multiple developability criteria and can take years to complete. In this context, artificial intelligence (AI), and especially machine learning (ML), have great potential to accelerate and improve the optimization of therapeutics, increasing their activity and safety as well as decreasing their development time and manufacturing costs. Artificial intelligence stands at the forefront of transforming antibody development. AI and machine learning (ML) algorithms can analyze vast datasets, uncover patterns, and predict outcomes with a speed and accuracy unattainable by human researchers.
The global AI-based Antibody Development Platform market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淎I-based Antibody Development Platform Industry Forecast鈥� looks at past sales and reviews total world AI-based Antibody Development Platform sales in 2022, providing a comprehensive analysis by region and market sector of projected AI-based Antibody Development Platform sales for 2023 through 2029. With AI-based Antibody Development Platform sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world AI-based Antibody Development Platform industry.
This Insight Report provides a comprehensive analysis of the global AI-based Antibody Development Platform landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on AI-based Antibody Development Platform portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global AI-based Antibody Development Platform market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for AI-based Antibody Development Platform and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global AI-based Antibody Development Platform.
United States market for AI-based Antibody Development Platform is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for AI-based Antibody Development Platform is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for AI-based Antibody Development Platform is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key AI-based Antibody Development Platform players cover Kyinno Biotechnolog, XtalPi Inc, DenovAI Biotech, immunitoAI Private Limited, EVQLV, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of AI-based Antibody Development Platform market by product type, application, key players and key regions and countries.
Segmentation by Type:
Antibody Generation and Screening
Discovery and Target Recognition
Engineering and Optimization
Other
Segmentation by Application:
Pharmaceutical
Biotechnology
Academic Research
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Antibody Generation and Screening
Discovery and Target Recognition
Engineering and Optimization
Other
Segmentation by Application:
Pharmaceutical
Biotechnology
Academic Research
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Kyinno Biotechnolog
XtalPi Inc
DenovAI Biotech
immunitoAI Private Limited
EVQLV
Creative Biolabs

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global AI-based Antibody Development Platform 麻豆原创 Size 2019-2030
2.1.2 AI-based Antibody Development Platform 麻豆原创 Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for AI-based Antibody Development Platform by Country/Region, 2019, 2023 & 2030
2.2 AI-based Antibody Development Platform Segment by Type
2.2.1 Antibody Generation and Screening
2.2.2 Discovery and Target Recognition
2.2.3 Engineering and Optimization
2.2.4 Other
2.3 AI-based Antibody Development Platform 麻豆原创 Size by Type
2.3.1 AI-based Antibody Development Platform 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global AI-based Antibody Development Platform 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 AI-based Antibody Development Platform Segment by Application
2.4.1 Pharmaceutical
2.4.2 Biotechnology
2.4.3 Academic Research
2.4.4 Others
2.5 AI-based Antibody Development Platform 麻豆原创 Size by Application
2.5.1 AI-based Antibody Development Platform 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global AI-based Antibody Development Platform 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 AI-based Antibody Development Platform 麻豆原创 Size by Player
3.1 AI-based Antibody Development Platform 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global AI-based Antibody Development Platform Revenue by Player (2019-2024)
3.1.2 Global AI-based Antibody Development Platform Revenue 麻豆原创 Share by Player (2019-2024)
3.2 Global AI-based Antibody Development Platform Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 AI-based Antibody Development Platform by Region
4.1 AI-based Antibody Development Platform 麻豆原创 Size by Region (2019-2024)
4.2 Global AI-based Antibody Development Platform Annual Revenue by Country/Region (2019-2024)
4.3 Americas AI-based Antibody Development Platform 麻豆原创 Size Growth (2019-2024)
4.4 APAC AI-based Antibody Development Platform 麻豆原创 Size Growth (2019-2024)
4.5 Europe AI-based Antibody Development Platform 麻豆原创 Size Growth (2019-2024)
4.6 Middle East & Africa AI-based Antibody Development Platform 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas AI-based Antibody Development Platform 麻豆原创 Size by Country (2019-2024)
5.2 Americas AI-based Antibody Development Platform 麻豆原创 Size by Type (2019-2024)
5.3 Americas AI-based Antibody Development Platform 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC AI-based Antibody Development Platform 麻豆原创 Size by Region (2019-2024)
6.2 APAC AI-based Antibody Development Platform 麻豆原创 Size by Type (2019-2024)
6.3 APAC AI-based Antibody Development Platform 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe AI-based Antibody Development Platform 麻豆原创 Size by Country (2019-2024)
7.2 Europe AI-based Antibody Development Platform 麻豆原创 Size by Type (2019-2024)
7.3 Europe AI-based Antibody Development Platform 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa AI-based Antibody Development Platform by Region (2019-2024)
8.2 Middle East & Africa AI-based Antibody Development Platform 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa AI-based Antibody Development Platform 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global AI-based Antibody Development Platform 麻豆原创 Forecast
10.1 Global AI-based Antibody Development Platform Forecast by Region (2025-2030)
10.1.1 Global AI-based Antibody Development Platform Forecast by Region (2025-2030)
10.1.2 Americas AI-based Antibody Development Platform Forecast
10.1.3 APAC AI-based Antibody Development Platform Forecast
10.1.4 Europe AI-based Antibody Development Platform Forecast
10.1.5 Middle East & Africa AI-based Antibody Development Platform Forecast
10.2 Americas AI-based Antibody Development Platform Forecast by Country (2025-2030)
10.2.1 United States 麻豆原创 AI-based Antibody Development Platform Forecast
10.2.2 Canada 麻豆原创 AI-based Antibody Development Platform Forecast
10.2.3 Mexico 麻豆原创 AI-based Antibody Development Platform Forecast
10.2.4 Brazil 麻豆原创 AI-based Antibody Development Platform Forecast
10.3 APAC AI-based Antibody Development Platform Forecast by Region (2025-2030)
10.3.1 China AI-based Antibody Development Platform 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 AI-based Antibody Development Platform Forecast
10.3.3 Korea 麻豆原创 AI-based Antibody Development Platform Forecast
10.3.4 Southeast Asia 麻豆原创 AI-based Antibody Development Platform Forecast
10.3.5 India 麻豆原创 AI-based Antibody Development Platform Forecast
10.3.6 Australia 麻豆原创 AI-based Antibody Development Platform Forecast
10.4 Europe AI-based Antibody Development Platform Forecast by Country (2025-2030)
10.4.1 Germany 麻豆原创 AI-based Antibody Development Platform Forecast
10.4.2 France 麻豆原创 AI-based Antibody Development Platform Forecast
10.4.3 UK 麻豆原创 AI-based Antibody Development Platform Forecast
10.4.4 Italy 麻豆原创 AI-based Antibody Development Platform Forecast
10.4.5 Russia 麻豆原创 AI-based Antibody Development Platform Forecast
10.5 Middle East & Africa AI-based Antibody Development Platform Forecast by Region (2025-2030)
10.5.1 Egypt 麻豆原创 AI-based Antibody Development Platform Forecast
10.5.2 South Africa 麻豆原创 AI-based Antibody Development Platform Forecast
10.5.3 Israel 麻豆原创 AI-based Antibody Development Platform Forecast
10.5.4 Turkey 麻豆原创 AI-based Antibody Development Platform Forecast
10.6 Global AI-based Antibody Development Platform Forecast by Type (2025-2030)
10.7 Global AI-based Antibody Development Platform Forecast by Application (2025-2030)
10.7.1 GCC Countries 麻豆原创 AI-based Antibody Development Platform Forecast
11 Key Players Analysis
11.1 Kyinno Biotechnolog
11.1.1 Kyinno Biotechnolog Company Information
11.1.2 Kyinno Biotechnolog AI-based Antibody Development Platform Product Offered
11.1.3 Kyinno Biotechnolog AI-based Antibody Development Platform Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Kyinno Biotechnolog Main Business Overview
11.1.5 Kyinno Biotechnolog Latest Developments
11.2 XtalPi Inc
11.2.1 XtalPi Inc Company Information
11.2.2 XtalPi Inc AI-based Antibody Development Platform Product Offered
11.2.3 XtalPi Inc AI-based Antibody Development Platform Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 XtalPi Inc Main Business Overview
11.2.5 XtalPi Inc Latest Developments
11.3 DenovAI Biotech
11.3.1 DenovAI Biotech Company Information
11.3.2 DenovAI Biotech AI-based Antibody Development Platform Product Offered
11.3.3 DenovAI Biotech AI-based Antibody Development Platform Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 DenovAI Biotech Main Business Overview
11.3.5 DenovAI Biotech Latest Developments
11.4 immunitoAI Private Limited
11.4.1 immunitoAI Private Limited Company Information
11.4.2 immunitoAI Private Limited AI-based Antibody Development Platform Product Offered
11.4.3 immunitoAI Private Limited AI-based Antibody Development Platform Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 immunitoAI Private Limited Main Business Overview
11.4.5 immunitoAI Private Limited Latest Developments
11.5 EVQLV
11.5.1 EVQLV Company Information
11.5.2 EVQLV AI-based Antibody Development Platform Product Offered
11.5.3 EVQLV AI-based Antibody Development Platform Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 EVQLV Main Business Overview
11.5.5 EVQLV Latest Developments
11.6 Creative Biolabs
11.6.1 Creative Biolabs Company Information
11.6.2 Creative Biolabs AI-based Antibody Development Platform Product Offered
11.6.3 Creative Biolabs AI-based Antibody Development Platform Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Creative Biolabs Main Business Overview
11.6.5 Creative Biolabs Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.